Clinical Trial

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-05-19; most recent amendment 2025-06-16.
Trial Details
NCT Number NCT05388695
Lead Sponsor Hebei Senlang Biotechnology Inc., Ltd.
Collaborators: Hebei Taihe Chunyu Biotechnology Co., Ltd
Conditions 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors
Enrollment 100 participants
Start Date 2022-04-08
Primary Completion 2027-03-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-18